189 related articles for article (PubMed ID: 30214190)
41. The promotion of siRNA delivery to breast cancer overexpressing epidermal growth factor receptor through anti-EGFR antibody conjugation by immunoliposomes.
Gao J; Liu W; Xia Y; Li W; Sun J; Chen H; Li B; Zhang D; Qian W; Meng Y; Deng L; Wang H; Chen J; Guo Y
Biomaterials; 2011 May; 32(13):3459-70. PubMed ID: 21296406
[TBL] [Abstract][Full Text] [Related]
42. Dual antitumoral potency of EG5 siRNA nanoplexes armed with cytotoxic bifunctional glutamyl-methotrexate targeting ligand.
Lee DJ; Kessel E; Edinger D; He D; Klein PM; Voith von Voithenberg L; Lamb DC; Lächelt U; Lehto T; Wagner E
Biomaterials; 2016 Jan; 77():98-110. PubMed ID: 26584350
[TBL] [Abstract][Full Text] [Related]
43. Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin.
Jiang J; Yang SJ; Wang JC; Yang LJ; Xu ZZ; Yang T; Liu XY; Zhang Q
Eur J Pharm Biopharm; 2010 Oct; 76(2):170-8. PubMed ID: 20600887
[TBL] [Abstract][Full Text] [Related]
44. Ultrasound enhanced siRNA delivery using cationic liposome-microbubble complexes for the treatment of squamous cell carcinoma.
Qin B; Chen X; Zhu J; Kopechek J; Helfield B; Yu F; Cyriac J; Lavery L; Grandis JR; Villanueva FS
Nanotheranostics; 2024; 8(3):285-297. PubMed ID: 38577322
[No Abstract] [Full Text] [Related]
45. Co-delivery of EGFR and BRD4 siRNA by cell-penetrating peptides-modified redox-responsive complex in triple negative breast cancer cells.
Zhang C; Yuan W; Wu Y; Wan X; Gong Y
Life Sci; 2021 Feb; 266():118886. PubMed ID: 33310044
[TBL] [Abstract][Full Text] [Related]
46. Enhanced therapeutic effect of Adriamycin on multidrug resistant breast cancer by the ABCG2-siRNA loaded polymeric nanoparticles assisted with ultrasound.
Bai M; Shen M; Teng Y; Sun Y; Li F; Zhang X; Xu Y; Duan Y; Du L
Oncotarget; 2015 Dec; 6(41):43779-90. PubMed ID: 26575421
[TBL] [Abstract][Full Text] [Related]
47. Novel functionalized nanoparticles for tumor-targeting co-delivery of doxorubicin and siRNA to enhance cancer therapy.
Xia Y; Xu T; Wang C; Li Y; Lin Z; Zhao M; Zhu B
Int J Nanomedicine; 2018; 13():143-159. PubMed ID: 29317822
[TBL] [Abstract][Full Text] [Related]
48. Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA.
Taratula O; Kuzmov A; Shah M; Garbuzenko OB; Minko T
J Control Release; 2013 Nov; 171(3):349-57. PubMed ID: 23648833
[TBL] [Abstract][Full Text] [Related]
49. Anti-EpCAM-conjugated adeno-associated virus serotype 2 for systemic delivery of EGFR shRNA: Its retargeting and antitumor effects on OVCAR3 ovarian cancer in vivo.
Lee S; Ahn HJ
Acta Biomater; 2019 Jun; 91():258-269. PubMed ID: 31026519
[TBL] [Abstract][Full Text] [Related]
50. Sortagged anti-EGFR immunoliposomes exhibit increased cytotoxicity on target cells.
Wöll S; Dickgiesser S; Rasche N; Schiller S; Scherließ R
Eur J Pharm Biopharm; 2019 Mar; 136():203-212. PubMed ID: 30677497
[TBL] [Abstract][Full Text] [Related]
51. Intratumoral delivery and therapeutic efficacy of nanoparticle-encapsulated anti-tumor siRNA following intrapulmonary administration for potential treatment of lung cancer.
Kanehira Y; Togami K; Ishizawa K; Sato S; Tada H; Chono S
Pharm Dev Technol; 2019 Nov; 24(9):1095-1103. PubMed ID: 31204552
[TBL] [Abstract][Full Text] [Related]
52. Combined anti-Galectin-1 and anti-EGFR siRNA-loaded chitosan-lipid nanocapsules decrease temozolomide resistance in glioblastoma: in vivo evaluation.
Danhier F; Messaoudi K; Lemaire L; Benoit JP; Lagarce F
Int J Pharm; 2015 Mar; 481(1-2):154-61. PubMed ID: 25644286
[TBL] [Abstract][Full Text] [Related]
53. Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer.
Kim GH; Won JE; Byeon Y; Kim MG; Wi TI; Lee JM; Park YY; Lee JW; Kang TH; Jung ID; Shin BC; Ahn HJ; Lee YJ; Sood AK; Han HD; Park YM
Drug Deliv; 2018 Nov; 25(1):1394-1402. PubMed ID: 29890852
[TBL] [Abstract][Full Text] [Related]
54. Specific Drug Delivery to Cancer Cells with Double-Imprinted Nanoparticles against Epidermal Growth Factor Receptor.
Canfarotta F; Lezina L; Guerreiro A; Czulak J; Petukhov A; Daks A; Smolinska-Kempisty K; Poma A; Piletsky S; Barlev NA
Nano Lett; 2018 Aug; 18(8):4641-4646. PubMed ID: 29969563
[TBL] [Abstract][Full Text] [Related]
55. Targeted nanomedicine with anti-EGFR scFv for siRNA delivery into triple negative breast cancer cells.
Nguyen PV; Hervé-Aubert K; David S; Lautram N; Passirani C; Chourpa I; Aubrey N; Allard-Vannier E
Eur J Pharm Biopharm; 2020 Dec; 157():74-84. PubMed ID: 33059006
[TBL] [Abstract][Full Text] [Related]
56. Effective Skin Cancer Treatment by Topical Co-delivery of Curcumin and STAT3 siRNA Using Cationic Liposomes.
Jose A; Labala S; Ninave KM; Gade SK; Venuganti VVK
AAPS PharmSciTech; 2018 Jan; 19(1):166-175. PubMed ID: 28639178
[TBL] [Abstract][Full Text] [Related]
57. Integrated hollow mesoporous silica nanoparticles for target drug/siRNA co-delivery.
Ma X; Zhao Y; Ng KW; Zhao Y
Chemistry; 2013 Nov; 19(46):15593-603. PubMed ID: 24123533
[TBL] [Abstract][Full Text] [Related]
58. Systemic delivery of siRNA via LCP nanoparticle efficiently inhibits lung metastasis.
Yang Y; Li J; Liu F; Huang L
Mol Ther; 2012 Mar; 20(3):609-15. PubMed ID: 22186791
[TBL] [Abstract][Full Text] [Related]
59. A tumor-targeting cRGD-EGFR siRNA conjugate and its anti-tumor effect on glioblastoma in vitro and in vivo.
He S; Cen B; Liao L; Wang Z; Qin Y; Wu Z; Liao W; Zhang Z; Ji A
Drug Deliv; 2017 Nov; 24(1):471-481. PubMed ID: 28181832
[TBL] [Abstract][Full Text] [Related]
60. Ultrasound-targeted microbubble destruction to deliver siRNA cancer therapy.
Carson AR; McTiernan CF; Lavery L; Grata M; Leng X; Wang J; Chen X; Villanueva FS
Cancer Res; 2012 Dec; 72(23):6191-9. PubMed ID: 23010078
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
